BioSpace News Archive

VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 13, 2020 at 8:30am Eastern Time to report second quarter ended June 30, 2020 financial results and to provide a corporate update. Thursday, August 13 @ 8:30amET From

Ligand Pharmaceuticals Incorporated reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates.

Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2020, and to provide a business overview. To access the live conference call, please dial (877) 354-4056 (domestic)

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside chats at the following upcoming August investor conferences: BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 1:00 p.m. ET. Wedbush PacGrow Healthcare Virtual Conference on Tue

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that it has entered into a common stock purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor. Upon execution of the purchase agreement, Lincoln Park made an initial purchase of $2 million of common stock at $0.57 per

Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that its Board of Directors has appointed Christine Ann Miller as President and Chief Executive Officer and member of the board, effective August 3, 2020. In April of this year, Melinta became privately owned by affiliates of healthcare investment firm Deerfield Management Company, L.P. (“

Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan Previously reported positive interim data from dose optimization part of study demonstrated 0.3 mg/kg dose of ALRN-6924, now being evaluated in expansion cohort, resulted in most robust chemoprotective effects

Company announces database lock and plans to report top-line data from global Phase 3 PRO2TECT program of vadadustat for treatment of anemia due to chronic kidney disease in adult patients not on dialysis

Karius, the world leader in liquid biopsy for infectious diseases, announced today active enrollment in a multicenter, prospective study that will evaluate the diagnostic value of the Karius ® Test for pneumonia in immunocompromised adult patients including those with hematological cancers. The Karius Test is a non-invasive bloo